ADD ANYTHING HERE OR JUST REMOVE IT…
Wrong menu selected
Acarix Acarix
  • Product

    Background

    • What is Coronary Artery Disease (CAD)?
    • Diagnosing CAD

    About the product

    • The CADScor® System
    • How does it work
  • Resources

    Testimonials

    • HCP stories
    • Patient stories

    References

    • Clinical Studies
    • Questionnaire
    • Downloads (US)
    • Downloads (EU)
    • Education

    Support

    • Training
    • FAQ
    • Reimbursement

    Physician Locator

    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Rights Issue/Warrant Program
    • Previous Rights Issue
    • Investor Presentations
  • Company

    Who we are

    • About Acarix
    • leadership
    • Join the team

    Get in touch

    • Contact us
    • Investigator Initiated Study
  • News
    • Press
    • Events
    • Social Media
Account
Search
Book a Demo
Acarix Acarix
Book a demo
Menu
author-avatar acarix
Annual, English, IR, Listing Regulation, News, Regulatory, Report
November 18, 2024
23 Apr 2024

Acarix AB’s Annual Report 2023

Acarix, a leader in advanced acoustic-based cardiac diagnostics, today announces that the Annual Report for 2023 is available as a pdf ...
Continue reading
author-avatar acarix
Annual, IR, Listing Regulation, News, Regulatory, Report, Swedish
November 18, 2024
23 Apr 2024

Acarix AB’s Årsredovisning 2023

Acarix, ledande inom avancerad akustikbaserad hjärtdiagnostik, meddelar idag att årsredovisning för 2023 finns tillg&au...
Continue reading
author-avatar acarix
Corporate Information, English, General meeting, IR, Listing Regulation, News, Notice, Regulatory
November 18, 2024
11 Apr 2024

NOTICE OF ANNUAL GENERAL MEETING IN ACARIX AB

The shareholders of Acarix AB, reg. no. 559009-0667 (the "Company"), are hereby invited to the annual general meeting on Tuesday 14 May...
Continue reading
author-avatar acarix
Corporate Information, General meeting, IR, Listing Regulation, News, Notice, Regulatory, Swedish
November 18, 2024
11 Apr 2024

KALLELSE TILL ÅRSSTÄMMA I ACARIX AB

Aktieägarna i Acarix AB, org.nr 559009-0667 ("Bolaget"), kallas härmed till årsstämma tisdagen den 14 maj 2024 kl....
Continue reading
author-avatar acarix
Corporate Information, English, IR, MAR, News, Other Corporate Information, Regulatory
November 18, 2024
11 Apr 2024

Acarix adopts new growth-focused business model and provides outlook update as part of our ongoing strategic review

Acarix, a leader in advanced acoustic- and algorithm-based cardiac diagnostics, announces the adoption of a new innovative usage-based ...
Continue reading
author-avatar acarix
Corporate Information, IR, MAR, News, Other Corporate Information, Regulatory, Swedish
November 18, 2024
11 Apr 2024

Acarix antar ny tillväxtfokuserad affärsmodell och ger en uppdatering av strategiska och finansiella mål

Acarix, ledande aktör inom akustik- och algoritmbaserad hjärtdiagnostik, tillkännager idag införandet av en ny inno...
Continue reading
author-avatar acarix
Corporate Information, English, IR, Listing Regulation, News, Other Corporate Information, Regulatory
November 18, 2024
20 Mar 2024

Acarix announces the outcome of the exercise of warrants of series 2024:U1 (TO2)

The Board of directors of Acarix AB ("Acarix" or the "Company") today announces the outcome of the exercise period for warrants of seri...
Continue reading
author-avatar acarix
Corporate Information, IR, Listing Regulation, News, Other Corporate Information, Regulatory, Swedish
November 18, 2024
20 Mar 2024

Acarix offentliggör utfall av utnyttjande av teckningsoptioner av serie 2024:U1 (TO2)

Styrelsen för Acarix AB (”Acarix” eller ”Bolaget”) offentliggör idag utfallet av utnyttjandeperioden ...
Continue reading
author-avatar acarix
Corporate Information, English, IR, Listing Regulation, News, Other Corporate Information, Regulatory
November 18, 2024
06 Mar 2024

The exercise period for Acarix warrants of series 2024:U1 (TO2) begins today

The exercise period for the warrants of series 2024:U1 (TO2) (the "Warrants") issued in connection with Acarix AB ("Acarix" or the "Com...
Continue reading
author-avatar acarix
Corporate Information, IR, Listing Regulation, News, Other Corporate Information, Regulatory, Swedish
November 18, 2024
06 Mar 2024

Idag inleds utnyttjandeperioden för Acarix teckningsoptioner av serie 2024:U1 (TO2)

Utnyttjandeperioden för de teckningsoptioner av serie 2024:U1 (TO2) (”Teckningsoptioner”) som emitterades i samband me...
Continue reading
author-avatar acarix
Corporate Information, English, General meeting, IR, Listing Regulation, News, Regulatory, Report of the AGM
November 18, 2024
21 Feb 2024

Announcement from Acarix’s extra general meeting

The extra general meeting of Acarix AB (the "Company") was held today on 21 February 2024 and the following resolution was passed by th...
Continue reading
author-avatar acarix
Corporate Information, General meeting, IR, Listing Regulation, News, Regulatory, Report of the AGM, Swedish
November 18, 2024
21 Feb 2024

Kommuniké från extra bolagsstämma i Acarix

Extra bolagsstämma i Acarix AB ("Bolaget") hölls idag den 21 februari 2024 varvid aktieägarna fattade följande besl...
Continue reading
  • ‹
  • 1
  • 2
  • 3
  • 4
  • 5
  • ›
  • »

Acarix AB

Jungmansgatan 12
211 19 Malmö
SE
info@acarix.com

Product

Background

  • What is Coronary Artery Disease (CAD)?
  • Diagnosing CAD

About the product

  • The CADScor® System
  • How does it work

Resources

Testimonials

  • HCP stories
  • Patient stories

Support

  • Training
  • FAQ

References

  • Clinical Studies
  • Downloads (US)
  • Downloads (EU)

Investors

  • Corporate Governance
  • General Meetings
  • Financial Reports and Calendar
  • The Acarix Share
  • Rights Issue
  • Investor Presentations

Company

Who we are

  • About Acarix
  • Management
  • Join the team

Get in touch

  • Contact us
  • LinkedIn
  • Twitter

News

  • Press
  • Events
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy
  • Cookie policy
  • Privacy Policy: Clinical Studies
  • Privacy Policy

Acarix, 2025. All rights reserved V6

  • Products
    • Background
    • What is Coronary Artery Disease
    • Diagnosing CAD
    • About the product
    • The Cadscor System
    • How Does it Work
  • Resources
    • Testimonial
    • HCP Stories
    • Patients Stories
    • References
    • Clinical Studies
    • Downloads (US)
    • Downloads (EU)
    • Support
    • Training
    • Faq
    • Reimbursement
    • Physician Locator
    • Germany
  • Investors
    • Corporate Governance
    • General Meetings
    • Financial Reports and Calendar
    • The Acarix Share
    • Right Issue
    • Previous Rights Issue
    • Investor Presentations
  • Company
    • Who we are
    • About Acarix
    • Leadership
    • Join The Team
    • Get in touch
    • Contact Us
    • Investigator Initiated Study
  • News
    • News
    • Press
    • Events
    • Socialmedia
Start typing to see products you are looking for.